And still 20% below 52 week high. I think if they get some more good contracts and more coverage then the share price will appreciate. I hope so. Many of the security companies are losing money and the street could care less. Vasco actually makes money and the street could care less. It is what it is.
What's truly amazing is that a Republican is visiting the facility. I was under the impression that the Republican Party didn't believe in science. At least that's what they say. Apparently there is at least one that does.
Vasco had stellar earnings but the shorts are covering without too much trouble. Seems to be an abundance of sellers. Vasco was down over a buck yesterday so today's rally, though nice, isn't very dramatic. Not a well covered stock by analyst so that could be part of the tepid response to very good earnings.
Clyde, you couldn't lead a one car parade. I'm quite sure there are few beyond your Tea Party hypocrites that value your opinion on anything.
I'm always suspect of people who either promote or suggest shorting any stock. I can see why they might share that with their clients but why would they share with the general public? I truly don't care what analyst think but since others do I do follow recommendations. Not because I value their judgment but because other investors may.
Do I understand the concern about the patent issue correctly? If Celgene loses then the patent expires in 2022. If they win the patent expires in 2024. So this drop is based on that two year differential.
You may be correct. At least they make money whereas many of the cyber security stocks don't. Anyway, I'll stay for awhile and see what happens. Thanks
Why do analyst downgrade or upgrade any particular stock? They are not just good neighbors they have selfish motives for sure. They want to make money and they want you to make it for them. Credit Suisse does make good chocolate and cheese. I'll give them credit for that.
Just completed 8 weeks of Harvoni. Virus not detectable at this point in time. Zero side effects. One pill per day. Some promising drugs in pipeline. New push into fatty liver disease (much larger market than Hep). Leader in HIV. Leader in Hep C. Money running out their ying yang. Guidance less than exaggerated expectations of the "street". Stock down by $5. Does it make sense. Of course not. This is market that punishes many good companies and rewards some real dogs. I'm not a day trader and have no intention of selling. If it goes down into the low to mid $90, I will buy more. Traders after hours are of no interest to me.
Initially up $2+ after beating estimates and declaring 43 cent dividend. Then down $5 because they said they would continue to do what they have been doing. I'm simply not smart enough to understand why. Gilead is not a one trick pony but apparently the "street" thinks it is. I own CELG too and they have taken a hit after posting very good quarterly results. I think perhaps I should sell these two stellar stocks and buy some dog that loses mucho money and provides nothing of benefit to humanity. Maybe it would go up.
I have three doses of Harvoni remaining on a 8 weeks treatment regime. After week 6 I had NO detectable virus. Had absolutely NO side effects. Gilead's Harvoni is FAR superior to Abbvie's considering the dosage required and the need to use Ribavirin in some cases. Harvoni is ONE pill per day! No side effects of any consequence other than maybe headaches experienced by some. I had ZERO side effects. Now that Gilead has lowered their price to be competitive with Abbvie and can not understand why any doctor would prescribe any treatment other than Harvoni.